Based in Newark, Taunia Markvicka, PharmD, MBA, helds responsibilities with Symbiomix Therapeutics, LLC, as chief commercial officer. She lead a host of solutions focused on preparation for Solosec commercialization, as well as life cycle plans tied to the FDA Qualified Infectious Disease Product. Taunia Markvicka has guided diverse aspects of launch of the bacterial vaginosis medication including building medical affairs support for publications and educational initiatives, payer and channel strategy support, forecasting and field sales for successful launch, positioning, messaging strategy. Notably lead the execution of a disease awareness campaign that lead to two award; Platinum with AVA digital and Bronze with PM360 pharma choice awards.

Dr. Markvicka previously served as senior vice president, chief commercial officer, and commercial strategist with Pacira Pharmaceuticals. She was tasked with leadership, building, and oversight of the successful launch of EXPAREL. EXPAREL is an innovative advancement for postsurgical pain control leading to decreases in opioid use. Opioid use following surgery is an important gateway to addiction. Her leadership at Pacira established the foundation for an ongoing education on the risks of opioids and expansion for EXPAREL to a number of surgical procedures.


With her husband, Taunia Markvicka is active with a number of organizations that help protect and preserve Lake Mohawk, where she volunteers with Earth Day and lake preservation activities.